Table 1. Sensitivity, specificity, positive predictive value, and negative predictive value for PSA and AMACR highly
specific for AP
15
Prostatic
markers
Sensitivity Specificity Positive predictive
value (PPV)
Negative predictive
value (NPV)
PSA 100% 90,6% 89,5% 100%
AMACR 66,7% 77,3% 86,1% 77,3%
Histopathological examination revealed scattered
atypical cells around the blood vessels, suggesting
metastasis (figure 2a). Immunohistochemistry was
positive for PSA and AMACR (figure 2b). These
finding strongly supported the diagnosis of
cutaneous spread of AP.
3 DISCUSSION
Cutaneous metastasis is defined as a spread of
malignant cells from a primary cancer to the skin.
The exact mechanism of metastasis remains unclear.
Malignant cells may spread beyond the prostate
through some hypotheses, such as direct infiltration,
lymphatic, hematogenous, or combination of these
routes (Rattanasirivilai et al., 2011; Rodriguez-Lojo
et al., 2016). A meta-analysis study by Krathen et al.
(2003) found the overall incidence of cutaneous
metastasis in 2003 was 5.3% from 20,380 cases. The
most common tumor which spread to the skin was
breast cancer, with an incidence of 24%. Skin
metastates from AP are rare, with an incidence of
0.7% (Crawford, 2009; Stanko et al., 2007).
AP favors bones and lymph nodes for its
metastases (Tengue et al., 2017; Brown et al., 2014).
The result of whole spine MRI and bone scan
revealed osteoblastic lesions as metastases to spine,
cranium, costae, sacroiliac, and ischium. For this
bone metastases, the patient had 30 radiotherapy
session and followed by bone directed therapy with
bisphosphonate injections once in a month for 24
months. Whole abdomen CT scan showed no para
aorta, para iliac, and inguinal lymphadenopathy.
Cutaneous metastases of PA have more than one
of clinical morphology, they most frequently appear
as nodules or papules in the abdominal wall,
inguinal region, anterior thigh, and near the
umbilicus as Sister Mary Joseph nodules (Mak et al.,
2014; Wang et al., 2008). They usually
asymptomatic and rarely ulcerated (AbAziz et al.,
2013).
Immunohistochemistry might aid to confirm the
origin tumor of cutaneous metastases (Rodriquez et
al., 2016). In our patient, the specimen was positive
for PSA and AMACR, strongly supported the
diagnosis of skin metastases from the patient’s AP.
PSA and AMACR staining is widely used to identify
metastasis of AP. PSA is a serine protease member
of the human glandular kallikrein family which is
highly specific for AP, because it is synthesized in
the prostate ductal and acinar epithelium. AMACR
is a peroxisomal and mitochondrial enzyme that
plays a key role in beta oxidation of fatty acid. It is
identified as being overexpressed in AP cells (Oh et
al., 2016).
4 CONCLUSION
Cutaneous spread of AP is rare, but it happens in
0.7% of all skin metastases cases. Patient’s complain
and physical appearance can vary from one patient
to another. Malignancy should always be kept in
mind when working up on diagnosis of unhealed
skin lesion after adequate local and systemic
treatment done. The combination of clinical history,
physical examination, laboratory tests, routine
pathology, and immunohistochemistry assay can
provide enough information for a diagnosis of
metastatic adenocarcinoma of the prostate.
REFERENCES
AbAziz, A., Mahaletchumy, T., & Chung, J. K., 2013.
Skin Manifestation of Unsuspecting Prostate Cancer
Detected by 18F-FDG PET/CT Performed To Assess
Underlying Multiple Myeloma. Nuclear medicine and
molecular imaging, 47(4), pp.285-288.
Alcaraz, I., Cerroni, L., Ruetten, A., Kutzner, H., &
Requena, L., 2012. Cutaneous metastases from
internal malignancies: a clinicopathologic and
immunohistochemical review. The American journal
of dermatopathology, 34(4), pp. 347-393.
Brown, G. T., Patel, V., & Lee, C. C. R., 2014. Cutaneous
metastasis of prostate cancer: a case report and review
of the literature with bioinformatics analysis of
multiple healthcare delivery networks. Journal of
cutaneous pathology, 41(6),pp. 524-528.
Crawford, E. D., 2009.. Understanding the epidemiology,
natural history, and key pathways involved in prostate
cancer. Urology, 73(5), S4-S10, . Available from:
http://dx.doi.org/10.1016/j.urology.2009.03.001.